AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

Japan’s nuclear watchdog on Wednesday formally disqualified a reactor in the country’s north-central region for a restart, ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Over the next five years, we forecast operating profit margin to expand approximately 500 basis points, from 12.6% in 2023 to high double digits, which we think can be achieved with a combination of ...

The Onagawa unit cleared safety screening in February 2020 under stricter safety standards set after the 2011 nuclear ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

IAEA scientific and technical publications can be searched by multiple parameters: year of publication, topic and type. Use the facets to input your search criteria or the text field to search by ...